Buttonwood Financial Advisors Inc. Has $638,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Buttonwood Financial Advisors Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,073 shares of the company’s stock after selling 81 shares during the quarter. Buttonwood Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $638,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of JNJ. Hibernia Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $27,000. FNY Investment Advisers LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter valued at $37,000. Tower View Wealth Management LLC raised its position in shares of Johnson & Johnson by 183.3% during the 3rd quarter. Tower View Wealth Management LLC now owns 255 shares of the company’s stock valued at $40,000 after acquiring an additional 165 shares during the last quarter. Creative Capital Management Investments LLC raised its position in shares of Johnson & Johnson by 43.0% during the 3rd quarter. Creative Capital Management Investments LLC now owns 286 shares of the company’s stock valued at $45,000 after acquiring an additional 86 shares during the last quarter. Finally, VitalStone Financial LLC bought a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $48,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $152.49 on Friday. The stock has a 50-day moving average price of $158.21 and a two-hundred day moving average price of $156.46. The stock has a market cap of $367.47 billion, a PE ratio of 11.04, a price-to-earnings-growth ratio of 2.65 and a beta of 0.53. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. Johnson & Johnson has a 1 year low of $144.95 and a 1 year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, topping analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The company had revenue of $21.40 billion during the quarter, compared to the consensus estimate of $21.02 billion. During the same period in the prior year, the business posted $2.35 EPS. The company’s quarterly revenue was down 9.7% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.65 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. Wells Fargo & Company cut shares of Johnson & Johnson from an “overweight” rating to an “equal weight” rating and dropped their target price for the company from $170.00 to $163.00 in a research report on Wednesday, December 13th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, February 6th. Morgan Stanley lowered their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a research report on Wednesday, January 24th. Raymond James upped their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the company an “outperform” rating in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 28th. Seven investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $177.31.

Insider Transactions at Johnson & Johnson

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the firm’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the completion of the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the sale, the insider now owns 4,099,575 shares of the company’s stock, valued at $105,810,030.75. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.